MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1465-542X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer ; volume:22 ; number:1 ; day:12 ; month:8 ; year:2020 ; pages:1-17 ; date:12.2020
Breast cancer research ; 22, Heft 1 (12.8.2020), 1-17, 12.2020

Creator: Portman, Neil
Milioli, Heloisa H.
Alexandrou, Sarah
Coulson, Rhiannon
Yong, Aliza
Fernandez, Kristine J.
Chia, Kee Ming
Halilovic, Ensar
Segara, Davendra
Parker, Andrew
Haupt, Sue
Haupt, Ygal
Tilley, Wayne D.
Swarbrick, Alex
Caldon, C. Elizabeth
Lim, Elgene

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13058-020-01318-2

URN: urn:nbn:de:101:1-2020100600153197250417

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Portman, Neil
Milioli, Heloisa H.
Alexandrou, Sarah
Coulson, Rhiannon
Yong, Aliza
Fernandez, Kristine J.
Chia, Kee Ming
Halilovic, Ensar
Segara, Davendra
Parker, Andrew
Haupt, Sue
Haupt, Ygal
Tilley, Wayne D.
Swarbrick, Alex
Caldon, C. Elizabeth
Lim, Elgene
SpringerLink (Online service)

Other Objects (12)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

CDK4/6 inhibition in luminal breast cancer

Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival

Identification of molecular mechanisms induced by CDK4/6 inhibition

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc −/+ ice

Hochschulschrift

Molecular basis for the inhibition of p53 by Mdmx and Mdm2

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

CDK4/6 inhibition in luminal breast cancer

Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival

Identification of molecular mechanisms induced by CDK4/6 inhibition

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc −/+ ice

Hochschulschrift

Molecular basis for the inhibition of p53 by Mdmx and Mdm2

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

CDK4/6 inhibition in luminal breast cancer

Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival

Identification of molecular mechanisms induced by CDK4/6 inhibition

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc −/+ ice

Hochschulschrift

Molecular basis for the inhibition of p53 by Mdmx and Mdm2

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

CDK4/6 inhibition in luminal breast cancer

Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival

Identification of molecular mechanisms induced by CDK4/6 inhibition

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc −/+ ice

Molecular basis for the inhibition of p53 by Mdmx and Mdm2

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

CDK4/6 inhibition in luminal breast cancer

Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival

Identification of molecular mechanisms induced by CDK4/6 inhibition

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc −/+ ice

Molecular basis for the inhibition of p53 by Mdmx and Mdm2

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

CDK4 inhibition diminishes p53 activation by MDM2 antagonists

Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer

CDK4/6 inhibition in luminal breast cancer

Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival

Identification of molecular mechanisms induced by CDK4/6 inhibition

CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma

Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc −/+ ice

Molecular basis for the inhibition of p53 by Mdmx and Mdm2

BH3-mimetics or DNA-damaging agents in combination with RG7388 overcome p53 mutation-induced resistance to MDM2 inhibition

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition

Related objects

Reset password